Business Context and Reporting Period
This Form 6-K filing by Tiziana Life Sciences Ltd, dated March 14, 2025, addresses a regulatory compliance matter regarding its listing status on the Nasdaq Capital Market. The report confirms the resolution of a prior non-compliance notification issued by Nasdaq on January 29, 2025.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is exclusively focused on corporate governance and listing status.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq Listing Rule 5550(a)(2). The Company previously failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. Compliance was regained on March 12, 2025, after the stock maintained a closing bid price of $1.00 or more for ten consecutive trading days. Consequently, the delisting risk associated with this specific rule is now closed.
Outlook and Risks
Management commentary indicates that the Company's securities will continue to be listed and traded on The Nasdaq Stock Market. No new risks, contingencies, or unusual items were disclosed in this specific filing beyond the resolution of the bid price deficiency.
Investor Verification Checklist
- Verify the current trading price of Tiziana Life Sciences Ltd to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the attached Exhibit 99.1 (Press Release) for any additional context regarding the stock price recovery.
- Monitor future filings for any recurrence of bid price non-compliance or other listing standard violations.